Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41591-020-1070-6 http://scihub22266oqcxt.onion/10.1038/s41591-020-1070-6 32884153!7671939!32884153     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32884153&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Nat+Med 2020 ; 26 (11): 1694-1700 Nephropedia Template TP {{tp|p=32884153|t=2020. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters |pdf=|usr=}}{{32884153}} gab.com Text Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters JO: Nat Med http://www.kidney.de/pget.php?&tw=1&pmid=32884153 #FOAvip Coronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness, but some individuals develop severe pneumonia, respiratory failure and death(1-4). Studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in hamsters(5-7) and nonhuman primates(8-10) have generally reported mild clinical disease, and preclinical SARS-CoV-2 vaccine studies have demonstrated reduction of viral replication in the upper and lower respiratory tracts in nonhuman primates(11-13). Here we show that high-dose intranasal SARS-CoV-2 infection in hamsters results in severe clinical disease, including high levels of virus replication in tissues, extensive pneumonia, weight loss and mortality in a subset of animals. A single immunization with an adenovirus serotype 26 vector-based vaccine expressing a stabilized SARS-CoV-2 spike protein elicited binding and neutralizing antibody responses and protected against SARS-CoV-2-induced weight loss, pneumonia and mortality. These data demonstrate vaccine protection against SARS-CoV-2 clinical disease. This model should prove useful for preclinical studies of SARS-CoV-2 vaccines, therapeutics and pathogenesis. Twit Text FOAVip Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters ????Nat Med http://www.kidney.de/pget.php?&tw=1&pmid=32884153 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32884153 #FOAvip English Wikipedia <ref>{{Cite pmid|32884153}}</ref> Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters #MMPMID32884153 Tostanoski LH; Wegmann F; Martinot AJ; Loos C; McMahan K; Mercado NB; Yu J; Chan CN; Bondoc S; Starke CE; Nekorchuk M; Busman-Sahay K; Piedra-Mora C; Wrijil LM; Ducat S; Custers J; Atyeo C; Fischinger S; Burke JS; Feldman J; Hauser BM; Caradonna TM; Bondzie EA; Dagotto G; Gebre MS; Jacob-Dolan C; Lin Z; Mahrokhian SH; Nampanya F; Nityanandam R; Pessaint L; Porto M; Ali V; Benetiene D; Tevi K; Andersen H; Lewis MG; Schmidt AG; Lauffenburger DA; Alter G; Estes JD; Schuitemaker H; Zahn R; Barouch DH Nat Med 2020[Nov]; 26 (11): 1694-1700 PMID32884153show ga Coronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness, but some individuals develop severe pneumonia, respiratory failure and death(1-4). Studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in hamsters(5-7) and nonhuman primates(8-10) have generally reported mild clinical disease, and preclinical SARS-CoV-2 vaccine studies have demonstrated reduction of viral replication in the upper and lower respiratory tracts in nonhuman primates(11-13). Here we show that high-dose intranasal SARS-CoV-2 infection in hamsters results in severe clinical disease, including high levels of virus replication in tissues, extensive pneumonia, weight loss and mortality in a subset of animals. A single immunization with an adenovirus serotype 26 vector-based vaccine expressing a stabilized SARS-CoV-2 spike protein elicited binding and neutralizing antibody responses and protected against SARS-CoV-2-induced weight loss, pneumonia and mortality. These data demonstrate vaccine protection against SARS-CoV-2 clinical disease. This model should prove useful for preclinical studies of SARS-CoV-2 vaccines, therapeutics and pathogenesis. |Adenoviridae/*genetics/immunology[MESH] |Animals[MESH] |Antibodies, Neutralizing/genetics/therapeutic use[MESH] |COVID-19 Vaccines/genetics/*therapeutic use[MESH] |COVID-19/mortality/pathology/*prevention & control/virology[MESH] |Cricetinae[MESH] |Disease Models, Animal[MESH] |Female[MESH] |Genetic Vectors[MESH] |Humans[MESH] |Male[MESH] |Mesocricetus[MESH] |SARS-CoV-2/genetics/*immunology[MESH] |Severity of Illness Index[MESH] |Spike Glycoprotein, Coronavirus/*genetics/*immunology[MESH] |Vaccines, Synthetic/genetics/therapeutic use[MESH]Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in ha(epmc).pdf DeepDyve Pubget Overpricing